Which has higher valuation & earnings, EVO or CDXS?

Codexis has lower revenue, but higher earnings than Evotec. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Evotec $891.97M 0.61 -$117.12M N/A N/A Codexis $70.39M 2.19 -$43.97M -$0.34 N/A

Is EVO or CDXS more profitable?

Evotec has a net margin of -26.20% compared to Codexis' net margin of -39.55%. Evotec's return on equity of -24.93% beat Codexis' return on equity. Company Net Margins Return on Equity Return on Assets Evotec -26.20% -24.93% -11.35% Codexis -39.55% -74.36% -23.58%

Does the media refer more to EVO or CDXS?

In the previous week, Evotec had 2 more articles in the media than Codexis. MarketBeat recorded 4 mentions for Evotec and 2 mentions for Codexis. Codexis' average media sentiment score of 0.91 beat Evotec's score of 0.13 indicating that Codexis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evotec 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Codexis 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is TKNO or CDXS more profitable?

Alpha Teknova has a net margin of -38.37% compared to Codexis' net margin of -39.55%. Alpha Teknova's return on equity of -24.94% beat Codexis' return on equity. Company Net Margins Return on Equity Return on Assets Alpha Teknova -38.37% -24.94% -16.53% Codexis -39.55% -74.36% -23.58%

Does the media prefer TKNO or CDXS?

In the previous week, Alpha Teknova and Alpha Teknova both had 2 articles in the media. Codexis' average media sentiment score of 0.91 beat Alpha Teknova's score of 0.54 indicating that Codexis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alpha Teknova 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Codexis 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is SLP or CDXS more profitable?

Simulations Plus has a net margin of 9.88% compared to Codexis' net margin of -39.55%. Simulations Plus' return on equity of 13.50% beat Codexis' return on equity. Company Net Margins Return on Equity Return on Assets Simulations Plus 9.88% 13.50% 12.45% Codexis -39.55% -74.36% -23.58%

Does the media refer more to SLP or CDXS?

In the previous week, Simulations Plus had 9 more articles in the media than Codexis. MarketBeat recorded 11 mentions for Simulations Plus and 2 mentions for Codexis. Codexis' average media sentiment score of 0.91 beat Simulations Plus' score of 0.45 indicating that Codexis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Simulations Plus 1 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Codexis 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is CDXS or LAB more profitable?

Standard BioTools has a net margin of 100.36% compared to Codexis' net margin of -39.55%. Standard BioTools' return on equity of -7.57% beat Codexis' return on equity. Company Net Margins Return on Equity Return on Assets Codexis -39.55% -74.36% -23.58% Standard BioTools 100.36% -7.57% -6.14%

Does the media prefer CDXS or LAB?

In the previous week, Standard BioTools had 2 more articles in the media than Codexis. MarketBeat recorded 4 mentions for Standard BioTools and 2 mentions for Codexis. Codexis' average media sentiment score of 0.91 beat Standard BioTools' score of 0.56 indicating that Codexis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Codexis 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Standard BioTools 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, CDXS or QSI?

Codexis has higher revenue and earnings than Quantum-Si. Codexis is trading at a lower price-to-earnings ratio than Quantum-Si, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Codexis $70.39M 2.19 -$43.97M -$0.34 N/A Quantum-Si $2.44M 137.25 -$101.34M -$0.46 N/A

Is CDXS or QSI more profitable?

Codexis has a net margin of -39.55% compared to Quantum-Si's net margin of -6,138.26%. Quantum-Si's return on equity of -47.12% beat Codexis' return on equity. Company Net Margins Return on Equity Return on Assets Codexis -39.55% -74.36% -23.58% Quantum-Si -6,138.26% -47.12% -43.18%

Does the media prefer CDXS or QSI?

In the previous week, Quantum-Si had 3 more articles in the media than Codexis. MarketBeat recorded 5 mentions for Quantum-Si and 2 mentions for Codexis. Codexis' average media sentiment score of 0.91 beat Quantum-Si's score of 0.14 indicating that Codexis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Codexis 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Quantum-Si 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Codexis (CDXS) Competitors

$1.41 +0.05 (+3.68%)

As of 10/9/2026 04:00 PM Eastern

Compare

CDXS vs. EVO, TKNO, SLP, LAB, and QSI

Should you buy Codexis stock or one of its competitors? Codexis's main competitors and comparable companies include Evotec (EVO), Alpha Teknova (TKNO), Simulations Plus (SLP), Standard BioTools (LAB), and Quantum-Si (QSI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Codexis compare to Evotec?

Evotec (NASDAQ:EVO) and Codexis (NASDAQ:CDXS) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability, media sentiment and analyst recommendations.

Evotec has a net margin of -26.20% compared to Codexis' net margin of -39.55%. Evotec's return on equity of -24.93% beat Codexis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evotec	-26.20%	-24.93%	-11.35%
Codexis	-39.55%	-74.36%	-23.58%

Evotec has a beta of 1.97, indicating that its share price is 97% more volatile than the broader market. Comparatively, Codexis has a beta of 2.55, indicating that its share price is 155% more volatile than the broader market.

Codexis has lower revenue, but higher earnings than Evotec.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evotec	$891.97M	0.61	-$117.12M	N/A	N/A
Codexis	$70.39M	2.19	-$43.97M	-$0.34	N/A

5.8% of Evotec shares are owned by institutional investors. Comparatively, 78.5% of Codexis shares are owned by institutional investors. 1.0% of Evotec shares are owned by company insiders. Comparatively, 3.5% of Codexis shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Evotec presently has a consensus price target of $3.00, suggesting a potential upside of 96.08%. Codexis has a consensus price target of $6.50, suggesting a potential upside of 360.99%. Given Codexis' stronger consensus rating and higher possible upside, analysts plainly believe Codexis is more favorable than Evotec.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evotec	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Codexis	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Evotec had 2 more articles in the media than Codexis. MarketBeat recorded 4 mentions for Evotec and 2 mentions for Codexis. Codexis' average media sentiment score of 0.91 beat Evotec's score of 0.13 indicating that Codexis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Evotec	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Codexis	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Codexis beats Evotec on 9 of the 14 factors compared between the two stocks.

How does Codexis compare to Alpha Teknova?

Alpha Teknova (NASDAQ:TKNO) and Codexis (NASDAQ:CDXS) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation, media sentiment and analyst recommendations.

Alpha Teknova has a net margin of -38.37% compared to Codexis' net margin of -39.55%. Alpha Teknova's return on equity of -24.94% beat Codexis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alpha Teknova	-38.37%	-24.94%	-16.53%
Codexis	-39.55%	-74.36%	-23.58%

13.8% of Alpha Teknova shares are owned by institutional investors. Comparatively, 78.5% of Codexis shares are owned by institutional investors. 13.2% of Alpha Teknova shares are owned by insiders. Comparatively, 3.5% of Codexis shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Alpha Teknova presently has a consensus target price of $8.00, suggesting a potential downside of 9.50%. Codexis has a consensus target price of $6.50, suggesting a potential upside of 360.99%. Given Codexis' higher possible upside, analysts plainly believe Codexis is more favorable than Alpha Teknova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alpha Teknova	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Codexis	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Alpha Teknova and Alpha Teknova both had 2 articles in the media. Codexis' average media sentiment score of 0.91 beat Alpha Teknova's score of 0.54 indicating that Codexis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alpha Teknova	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Codexis	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Alpha Teknova has higher earnings, but lower revenue than Codexis. Alpha Teknova is trading at a lower price-to-earnings ratio than Codexis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alpha Teknova	$40.52M	11.70	-$17.26M	-$0.31	N/A
Codexis	$70.39M	2.19	-$43.97M	-$0.34	N/A

Alpha Teknova has a beta of 0.85, indicating that its stock price is 15% less volatile than the broader market. Comparatively, Codexis has a beta of 2.55, indicating that its stock price is 155% more volatile than the broader market.

Summary

Alpha Teknova beats Codexis on 9 of the 15 factors compared between the two stocks.

How does Codexis compare to Simulations Plus?

Simulations Plus (NASDAQ:SLP) and Codexis (NASDAQ:CDXS) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, media sentiment, risk, dividends and earnings.

Codexis has lower revenue, but higher earnings than Simulations Plus. Codexis is trading at a lower price-to-earnings ratio than Simulations Plus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Simulations Plus	$82.06M	4.56	-$64.72M	$0.40	46.25
Codexis	$70.39M	2.19	-$43.97M	-$0.34	N/A

Simulations Plus presently has a consensus target price of $17.25, suggesting a potential downside of 6.76%. Codexis has a consensus target price of $6.50, suggesting a potential upside of 360.99%. Given Codexis' stronger consensus rating and higher probable upside, analysts clearly believe Codexis is more favorable than Simulations Plus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Simulations Plus	1 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.88
Codexis	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Simulations Plus had 9 more articles in the media than Codexis. MarketBeat recorded 11 mentions for Simulations Plus and 2 mentions for Codexis. Codexis' average media sentiment score of 0.91 beat Simulations Plus' score of 0.45 indicating that Codexis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Simulations Plus	1 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Codexis	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Simulations Plus has a beta of 1.31, meaning that its share price is 31% more volatile than the broader market. Comparatively, Codexis has a beta of 2.55, meaning that its share price is 155% more volatile than the broader market.

78.1% of Simulations Plus shares are held by institutional investors. Comparatively, 78.5% of Codexis shares are held by institutional investors. 19.1% of Simulations Plus shares are held by insiders. Comparatively, 3.5% of Codexis shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Simulations Plus has a net margin of 9.88% compared to Codexis' net margin of -39.55%. Simulations Plus' return on equity of 13.50% beat Codexis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Simulations Plus	9.88%	13.50%	12.45%
Codexis	-39.55%	-74.36%	-23.58%

Summary

Simulations Plus beats Codexis on 9 of the 16 factors compared between the two stocks.

How does Codexis compare to Standard BioTools?

Codexis (NASDAQ:CDXS) and Standard BioTools (NASDAQ:LAB) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, analyst recommendations, dividends, institutional ownership and risk.

Codexis has higher earnings, but lower revenue than Standard BioTools. Codexis is trading at a lower price-to-earnings ratio than Standard BioTools, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Codexis	$70.39M	2.19	-$43.97M	-$0.34	N/A
Standard BioTools	$85.33M	3.17	-$74.90M	$0.22	3.13

Codexis has a beta of 2.55, suggesting that its share price is 155% more volatile than the broader market. Comparatively, Standard BioTools has a beta of 1.36, suggesting that its share price is 36% more volatile than the broader market.

78.5% of Codexis shares are owned by institutional investors. Comparatively, 53.7% of Standard BioTools shares are owned by institutional investors. 3.5% of Codexis shares are owned by insiders. Comparatively, 26.8% of Standard BioTools shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Standard BioTools had 2 more articles in the media than Codexis. MarketBeat recorded 4 mentions for Standard BioTools and 2 mentions for Codexis. Codexis' average media sentiment score of 0.91 beat Standard BioTools' score of 0.56 indicating that Codexis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Codexis	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Standard BioTools	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Codexis currently has a consensus target price of $6.50, indicating a potential upside of 360.99%. Standard BioTools has a consensus target price of $1.35, indicating a potential upside of 95.82%. Given Codexis' stronger consensus rating and higher possible upside, analysts clearly believe Codexis is more favorable than Standard BioTools.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Codexis	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Standard BioTools	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Standard BioTools has a net margin of 100.36% compared to Codexis' net margin of -39.55%. Standard BioTools' return on equity of -7.57% beat Codexis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Codexis	-39.55%	-74.36%	-23.58%
Standard BioTools	100.36%	-7.57%	-6.14%

Summary

Standard BioTools beats Codexis on 9 of the 16 factors compared between the two stocks.

How does Codexis compare to Quantum-Si?

Codexis (NASDAQ:CDXS) and Quantum-Si (NASDAQ:QSI) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, earnings, risk, valuation, profitability, media sentiment and analyst recommendations.

Codexis presently has a consensus price target of $6.50, indicating a potential upside of 360.99%. Quantum-Si has a consensus price target of $2.50, indicating a potential upside of 63.40%. Given Codexis' higher possible upside, research analysts plainly believe Codexis is more favorable than Quantum-Si.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Codexis	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Quantum-Si	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Quantum-Si had 3 more articles in the media than Codexis. MarketBeat recorded 5 mentions for Quantum-Si and 2 mentions for Codexis. Codexis' average media sentiment score of 0.91 beat Quantum-Si's score of 0.14 indicating that Codexis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Codexis	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Quantum-Si	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Codexis has a beta of 2.55, indicating that its stock price is 155% more volatile than the broader market. Comparatively, Quantum-Si has a beta of 3.21, indicating that its stock price is 221% more volatile than the broader market.

Codexis has higher revenue and earnings than Quantum-Si. Codexis is trading at a lower price-to-earnings ratio than Quantum-Si, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Codexis	$70.39M	2.19	-$43.97M	-$0.34	N/A
Quantum-Si	$2.44M	137.25	-$101.34M	-$0.46	N/A

Codexis has a net margin of -39.55% compared to Quantum-Si's net margin of -6,138.26%. Quantum-Si's return on equity of -47.12% beat Codexis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Codexis	-39.55%	-74.36%	-23.58%
Quantum-Si	-6,138.26%	-47.12%	-43.18%

78.5% of Codexis shares are owned by institutional investors. Comparatively, 39.9% of Quantum-Si shares are owned by institutional investors. 3.5% of Codexis shares are owned by insiders. Comparatively, 22.0% of Quantum-Si shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Codexis beats Quantum-Si on 8 of the 14 factors compared between the two stocks.

Get Codexis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CDXS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CDXS vs. The Competition

Export

Metric	Codexis	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$154.40M	$10.58B	$7.25B	$13.30B
Dividend Yield	N/A	1.45%	2.52%	22.58%
P/E Ratio	-4.15	32.42	275.29	26.14
Price / Sales	2.19	106.94	582.85	87.88
Price / Cash	N/A	27.28	76.96	53.71
Price / Book	2.52	6.48	11.22	6.33
Net Income	-$43.97M	$56.67B	$3.50B	$382.15M
7 Day Performance	3.68%	-1.01%	-0.89%	-1.40%
1 Month Performance	-3.75%	9.16%	-4.02%	-3.35%
1 Year Performance	-45.56%	32.19%	7.13%	1.49%

Codexis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CDXS Codexis	2.5658 of 5 stars	$1.41 +3.7%	$6.50 +361.0%	-45.6%	$154.40M	$70.39M	N/A	146	Analyst Downgrade
EVO Evotec	3.5628 of 5 stars	$1.65 -3.8%	$3.00 +82.4%	-60.5%	$608.45M	$891.97M	N/A	4,553	Short Interest Decrease
TKNO Alpha Teknova	1.4764 of 5 stars	$8.86 -0.4%	$8.00 -9.7%	+78.2%	$477.17M	$40.52M	N/A	158
SLP Simulations Plus	1.0631 of 5 stars	$18.49 +0.3%	$17.25 -6.7%	N/A	$372.74M	$79.18M	46.23	213	Analyst Forecast High Trading Volume
LAB Standard BioTools	3.3967 of 5 stars	$0.73 -1.7%	$1.35 +85.4%	-46.1%	$290.74M	$85.33M	3.31	389

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CDXS) was last updated on 10/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Codexis (CDXS) Competitors

CDXS vs. EVO, TKNO, SLP, LAB, and QSI

How does Codexis compare to Evotec?

Summary

How does Codexis compare to Alpha Teknova?

Summary

How does Codexis compare to Simulations Plus?

Summary

How does Codexis compare to Standard BioTools?

Summary

How does Codexis compare to Quantum-Si?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CDXS vs. The Competition

Codexis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Codexis (CDXS) Competitors

CDXS vs. EVO, TKNO, SLP, LAB, and QSI

How does Codexis compare to Evotec?

Is EVO or CDXS more profitable?

Which has more risk & volatility, EVO or CDXS?

Which has higher valuation & earnings, EVO or CDXS?

Do institutionals and insiders have more ownership in EVO or CDXS?

Do analysts prefer EVO or CDXS?

Does the media refer more to EVO or CDXS?

Summary

How does Codexis compare to Alpha Teknova?

Is TKNO or CDXS more profitable?

Do insiders & institutionals hold more shares of TKNO or CDXS?

Do analysts prefer TKNO or CDXS?

Does the media prefer TKNO or CDXS?

Which has stronger valuation and earnings, TKNO or CDXS?

Which has more volatility and risk, TKNO or CDXS?

Summary

How does Codexis compare to Simulations Plus?

Which has higher valuation and earnings, SLP or CDXS?

Do analysts prefer SLP or CDXS?

Does the media refer more to SLP or CDXS?

Which has more volatility & risk, SLP or CDXS?

Do institutionals and insiders believe in SLP or CDXS?

Is SLP or CDXS more profitable?

Summary

How does Codexis compare to Standard BioTools?

Which has better valuation and earnings, CDXS or LAB?

Which has more risk and volatility, CDXS or LAB?

Do insiders & institutionals believe in CDXS or LAB?

Does the media prefer CDXS or LAB?

Do analysts rate CDXS or LAB?

Is CDXS or LAB more profitable?

Summary

How does Codexis compare to Quantum-Si?

Do analysts rate CDXS or QSI?

Does the media prefer CDXS or QSI?

Which has more volatility and risk, CDXS or QSI?

Which has higher valuation and earnings, CDXS or QSI?

Is CDXS or QSI more profitable?

Do insiders & institutionals believe in CDXS or QSI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CDXS vs. The Competition

Codexis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools